{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:04:29Z","timestamp":1790877869378,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007659","name":"Bayer Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","kidneymedicinejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney Medicine"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.xkme.2026.101484","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:26:40Z","timestamp":1785770800000},"page":"101484","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk of Progression and Costs of Care for Patients With Chronic Kidney Disease"],"prefix":"10.1016","volume":"8","author":[{"given":"Navdeep","family":"Tangri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith A.","family":"Betts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxian","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind","family":"Katta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef M.K.","family":"Farag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel T.","family":"Fatoba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reid","family":"Whitlock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan J.","family":"Bamforth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia J.","family":"Leon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay K.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4 Suppl 1","key":"10.1016\/j.xkme.2026.101484_bib1","doi-asserted-by":"crossref","first-page":"A8","DOI":"10.1053\/j.ajkd.2024.01.001","article-title":"US Renal Data System 2023 Annual Data Report: Epidemiology of Kidney Disease in the United States","volume":"83","author":"Johansen","year":"2024","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1016\/j.xkme.2026.101484_bib2","doi-asserted-by":"crossref","first-page":"554","DOI":"10.34067\/KID.0007572021","article-title":"Artificial intelligence in the identification, management, and follow-up of CKD","volume":"3","author":"Tangri","year":"2022","journal-title":"Kidney360"},{"issue":"15","key":"10.1016\/j.xkme.2026.101484_bib3","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1001\/jama.2011.451","article-title":"A predictive model for progression of chronic kidney disease to kidney failure","volume":"305","author":"Tangri","year":"2011","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.xkme.2026.101484_bib4","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.ekir.2022.05.004","article-title":"Development and external validation of a machine learning model for progression of CKD","volume":"7","author":"Ferguson","year":"2022","journal-title":"Kidney Int Rep"},{"issue":"4","key":"10.1016\/j.xkme.2026.101484_bib5","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfae052","article-title":"Validation of the Klinrisk chronic kidney disease progression model in the FIDELITY population","volume":"17","author":"Tangri","year":"2024","journal-title":"Clin Kidney J"},{"issue":"8","key":"10.1016\/j.xkme.2026.101484_bib6","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1111\/dom.15678","article-title":"Machine learning for prediction of chronic kidney disease progression: validation of the Klinrisk model in the CANVAS program and CREDENCE trial","volume":"26","author":"Tangri","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.xkme.2026.101484_bib7","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1681\/ASN.0000000817","article-title":"Validation of the Klinrisk machine learning model for CKD progression in a large representative US population","volume":"37","author":"Tangri","year":"2026","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"10.1016\/j.xkme.2026.101484_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2022.100532","article-title":"CKD progression and economic burden in individuals with CKD associated with type 2 diabetes","volume":"4","author":"Mullins","year":"2022","journal-title":"Kidney Med"},{"issue":"3","key":"10.1016\/j.xkme.2026.101484_bib12","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1214\/08-AOAS169","article-title":"Random survival forests","volume":"2","author":"Ishwaran","year":"2008","journal-title":"Ann Appl Stat"},{"issue":"1","key":"10.1016\/j.xkme.2026.101484_bib13","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","year":"2013","journal-title":"Kidney Int Suppl"},{"issue":"3","key":"10.1016\/j.xkme.2026.101484_bib14","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"issue":"1","key":"10.1016\/j.xkme.2026.101484_bib15","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1186\/s12913-024-11258-8","article-title":"Territory Kidney Care Steering Committee. Costs and healthcare use of patients with chronic kidney disease in the Northern Territory, Australia","volume":"24","author":"Chen","year":"2024","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"10.1016\/j.xkme.2026.101484_bib16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2215\/CJN.06770521","article-title":"Kidney failure risk equation and cost of care in patients with chronic kidney disease","volume":"17","author":"Prasad","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.xkme.2026.101484_bib17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1053\/j.ajkd.2020.07.011","article-title":"Novel risk factors for progression of diabetic and nondiabetic CKD: findings from the Chronic Renal Insufficiency Cohort (CRIC) study","volume":"77","author":"Anderson","year":"2021","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.xkme.2026.101484_bib18","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1080\/0886022X.2022.2106872","article-title":"Prognosis and risk factors of chronic kidney disease progression in patients with diabetic kidney disease and non-diabetic kidney disease: a prospective cohort CKD-ROUTE study","volume":"44","author":"Chen","year":"2022","journal-title":"Ren Fail"},{"issue":"8","key":"10.1016\/j.xkme.2026.101484_bib19","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1681\/ASN.0000000000000377","article-title":"Individualized risk of CKD progression among US adults","volume":"35","author":"Tio","year":"2024","journal-title":"J Am Soc Nephrol"},{"issue":"15","key":"10.1016\/j.xkme.2026.101484_bib20","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.xkme.2026.101484_bib21","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.xkme.2026.101484_bib22","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.xkme.2026.101484_bib23","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","article-title":"Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria","volume":"149","author":"Neuen","year":"2024","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.xkme.2026.101484_bib24","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2023.1502","article-title":"Reframing value-based care management: beyond cost reduction and toward patient centeredness","volume":"4","author":"Wang","year":"2023","journal-title":"JAMA Health Forum"},{"issue":"4 suppl 2","key":"10.1016\/j.xkme.2026.101484_bib25","first-page":"S87","article-title":"Baseline characteristics and early results from the GEMINI-RAPA project: improving the quality of CKD care with risk prediction and personalized recommendations [abstract 285]","volume":"83","author":"Tangri","year":"2024","journal-title":"Am J Kidney Dis"}],"container-title":["Kidney Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059526002463?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059526002463?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:33:17Z","timestamp":1790875997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590059526002463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2590059526002463"],"URL":"https:\/\/doi.org\/10.1016\/j.xkme.2026.101484","relation":{},"ISSN":["2590-0595"],"issn-type":[{"value":"2590-0595","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of Progression and Costs of Care for Patients With Chronic Kidney Disease","name":"articletitle","label":"Article Title"},{"value":"Kidney Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xkme.2026.101484","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101484"}}